Dror Ortho-Design, Inc.

Dror Ortho-Design, Inc. is a development-stage medical device company focused on disrupting the orthodontic aligner market with its proprietary ZSmile platform. The company's core innovation is a single smart aligner that uses pulsating air technology to correct malocclusions, intended for nighttime use—a key differentiator from all-day aligner solutions. The company recently achieved a significant regulatory milestone with FDA 510(k) clearance for ZSmile in February 2026, positioning it for commercialization in the U.S. market. The target market is substantial, with the global clear aligners market projected to reach $56.8 billion by 2033.

Financially, the company is in a pre-revenue stage with a high-risk profile. As of December 31, 2025, it reported an accumulated deficit of $22.1 million and a cash position of only $228,540. The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses and insufficient liquidity. The proposed offering aims to raise approximately $13.0 million in net proceeds, which is critical for funding working capital and general corporate purposes. The company has also secured bridge financing through convertible promissory notes, indicating reliance on external funding to sustain operations.

The offering involves 3,636,364 shares of Common Stock at an assumed price of $4.13 per share, accompanied by a 1-for-550 reverse stock split. This split is intended to meet Nasdaq listing requirements, though approval is not guaranteed. The company plans to list on the Nasdaq Capital Market under the ticker "DROR." Post-offering, the company will have approximately 5.4 million shares outstanding, excluding shares underlying outstanding warrants, options, and convertible preferred stock. Investors face significant dilution risks from these outstanding securities.

Key risks include the company's lack of commercialization history, intense competition from established players like Align Technologies, and geopolitical risks due to its operations in Israel. The company's ability to successfully commercialize ZSmile, achieve market acceptance, and secure additional financing will be critical determinants of its future success. Management's experience in healthcare and technology provides some strategic capability, but the path to profitability remains uncertain and highly speculative.